How do I buy Grail Inc (GRAL) stock?

Buying Grail Inc (GRAL) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "GRAL", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy GRAL by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for GRAL on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Grail Inc from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Grail Inc (GRAL) pay dividends?

At the moment, Grail Inc (GRAL) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track GRAL's performance via the price chart in the Gotrade app.

Is buying GRAL on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy GRAL?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if GRAL is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Grail Inc (GRAL) Stock Price Today & Analysis

% positive news of 10 articles

published over the past 14 days

Latest news

The Motley Fool

Here's Why Grail Stock Surged 55% This Week

NeutralGRALSeptember 25, 2026

The Motley FoolNeutral

Here's Why Grail Stock Surged 55% This Week

GRAL

Stocktwits

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

NeutralGRALSeptember 25, 2026

StocktwitsNeutral

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

GRAL

Investors Business Daily

Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test

NeutralGRALSeptember 24, 2026

Investors Business DailyNeutral

Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test

GRAL

Stocktwits

GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness

NeutralGRALSeptember 23, 2026

StocktwitsNeutral

GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness

GRAL

Reuters

GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes

NeutralGRALSeptember 21, 2026

StocktwitsNeutral

GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes

GRAL

Reuters

Grail rallies as FDA staff flags no major concerns for multi-cancer test

NeutralGRALSeptember 21, 2026

ReutersNeutral

Grail rallies as FDA staff flags no major concerns for multi-cancer test

GRAL

Investors Business Daily

Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

NeutralGRALSeptember 21, 2026

Investors Business DailyNeutral

Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

GRAL

The Motley Fool

Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000

NeutralGRALSeptember 9, 2026

The Motley FoolNeutral

Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000

GRAL

About Grail Inc

GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal residual disease post-diagnostic tests. GRAIL, Inc. has market capitalization Approximately $754 million. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

SectorHealthcare

IndustryDiagnostics & Research

Employees910

CEODr. Joshua J. Ofman M.D., M.S.H.S

IPO DateJun 25, 2024

HeadquartersMenlo Park, CA

Key Executives

Name	Title	Year Born
Dr. Joshua J. Ofman M.D., M.S.H.S	CEO & Director	1965
Mr. Aaron Freidin	CFO & Head of Corporate Development	1979
Mr. Robert P. Ragusa	Advisor	1960
Mr. Paul Ciccolella	Senior Vice President of Global Development & Operations	—
Dr. Satnam Alag Ph.D.	Chief Technology Officer	—
Sir Harpal S. Kumar M.A., M.B.A., MEng	Chief Scientific Officer and President of Global Clinical & Medical Affairs	—
Mr. Abram Barth J.D., M.P.H.	Chief Legal Officer & Corporate Secretary	—
Ms. Trish Rowland	Senior Vice President of Corporate Communications	—
Ms. Alison Highlander	Chief People Officer	—
Mr. Andrew John Partridge	Chief Growth Officer	1969

Fundamentals

Valuation

Market cap$5.67B

Price-to-sales ratio29.33

Price-to-book value1.91

Price-earnings ratio-12.40

Return on Equity-16.00%

Return on Sales-330.00%

Return on Assets-14.00%

PEG ratioN/A

Earnings Per Share

Earnings Per Share$-9.69

Income Statement

Average volume1,194,275

EBITDA$-359.76M

1 year high (52w)$126.81

1 year low (52w)$41.50

Dividend

Ex dividend dateN/A

Dividend amount$0.00

Dividend yield0.00%

Last payment dateN/A

Dividend yield (TTM)N/A

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsBuy5 Indicators

Moving AveragesStrong Buy12 Indicators

What the experts say

4 Wall Street Analyst Ratings

HOLD

50% Buy

50% Hold

0% Sell

Target price

$101.75

Est return

19.18%

UBS

Doug Schenkel

Buy

Target price

$105.00

Est return

18.50%

RBC Capital

Dan Leonard

Hold

Target price

$84.00

Est return

34.80%

Baird

Catherine Schulte

Buy

Target price

$118.00

Est return

8.41%

Mizuho

Bradley Bowers

Hold

Target price

$100.00

Est return

22.38%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2024						-9.6	+2.8	-15.2	+3.8	+2.4	+29.2	-4.7
2025	+69.0	+33.7	-29.7	+37.5	+18.2	+37.1	-30.5	+0.0	+87.1	+48.1	+22.9	-12.9
2026	+10.1	-48.7	-1.8	+1.6	+32.6	+6.0	+0.7	+13.0	+59.0

Grail Inc (GRAL) Stock

Fundamentals

Recent news

Here's Why Grail Stock Surged 55% This Week

Here's Why Grail Stock Surged 55% This Week

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test

Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test

GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness

GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Here's Why Grail Stock Surged 55% This Week

Here's Why Grail Stock Surged 55% This Week

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test

Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test

GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness

GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness

FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy

FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy

The Holy Grail In Cancer? FDA Mulls New Blood Tests.

The Holy Grail In Cancer? FDA Mulls New Blood Tests.

GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes

GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes

Grail rallies as FDA staff flags no major concerns for multi-cancer test

Grail rallies as FDA staff flags no major concerns for multi-cancer test

Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000

Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000

About Grail Inc

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade